Biotronik touts Orsiro data at Japanese conference

Biotronik touted data today from the BioFlow-IV study of its Orsiro hybrid drug-eluting stent at this year’s Japan Circulation Society congress.

The company’s study enrolled 579 patients with de novo coronary lesions and randomized them to receive either the Orsiro stent or Xience stent. After 12 months, the researchers confirmed non-inferiority of its stent, based on the primary endpoint of target vessel failure.

Get the full story at our sister site, Drug Delivery Business News.

The post Biotronik touts Orsiro data at Japanese conference appeared first on MassDevice.

from MassDevice http://ift.tt/2n0o2w2